Case	Time points	Primary subtype		Secondary subtype	
		Prot	RT	Prot	RT
		B subtype		BF recombinant (not CRF12)	
C1	S1	NONE	M41L/ M184V/ Y188L/ L210W/ T215Y <sup>21</sup> V106I, H221Y and D67N <sup>(A)</sup>	NONE	NONE
	S2	L10I/ I15V/ M46I/ L63P/ I84V/ I85V/ L90M <sup>12</sup> M36I and F53L/ A71T <sup>(A)</sup>	M41L/ D67N/ L210W/ T215Y <sup>12</sup>	NON DETECTED	
C2		CRF12_BF		B subtype	
		NONE	NONE	I84V/ L90M	M41L/ K70E/ L210W/ T215Y
С3		B subtype		CRF12_BF	
		NONE	K103N <sup>1</sup>	NONE	NONE
		CRF12_BF		B subtype	
C4	<b>S</b> 1	$I47V^1$	NONE	NONE	NONE
	S2	NONE	$K70R^1$		NON DETECTED
		CRF12_BF		BF recombinant (not CRF12)	
C5	<b>S</b> 1	NONE	Y181C/ H221Y <sup>2</sup>	NON DETECTED	
	S2	NONE	Y181C <sup>1</sup>	NONE	NONE

**Table 2:** Evolution of antiretroviral resistance mutations in HIV-1 individuals with dual infections

A mean of sixteen sequences and/ or clones per sample were analyzed with Stanford software. Resistance mutations separeted by bars indicate combination of mutations in the sequences. The number indicated by superscript shows the number of sequences or clones with the corresponding mutation or combination of mutations.

(A) Each mutation in different sequences and carrying the combination of mutations indicated.